Encore Therapeutics (ETI) has successfully completed a pre-clinical Proof of Concept (POC) study on ETI-511, its proprietary, extended release phospholipid gel depot formulation of the NSAID drug meloxicam (Mobec) as a treatment for pain and inflammation.

The POC study demonstrated that ETI-511 provided about 100-fold higher local tissue levels of meloxicam for at least 48 hours around the injection site compared to orally dosed meloxicam, while exhibiting lower plasma meloxicam levels at all times compared to oral dosing.

ETI-511 was found to be well tolerated locally and systemically following subcutaneous injections.

ETI chairman and CEO Paul Marangos said the ability of ETI-511 to deliver localised high levels of meloxicam for extended periods has the potential to expand the clinical utility of meloxicam to treat pain and inflammatory disorders.

”ETI is now seeking a development partner to further develop ETI-511," Marangos said.


How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.